BCL2 and cancer: And this in fact has formed the basis for developing peptide or small molecule mimetics of these “sensitizing” BH3-only proteins, as a way to therapeutically adjust the Bcl-2 rheostat to favor cell death instead of cell survival in the cancer setting [5, 10].